Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).

被引：1
|
作者：
Moy, B.
Lebrun, F.
Bellet, M.
Chow, L.
Lang, I.
Xu, B.
Badwe, R. A.
Hershman, D. L.
Leip, E.
Bardy-Bouxin, N.
Duvillie, L.
Neven, P.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Unimed Med Inst, Comprehens Ctr Breast Dis, Hong Kong, Hong Kong, Peoples R China
[5] Orszagos Onkol Intezet, Budapest, Hungary
[6] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[7] Tata Mem Hosp, Bombay 400012, Maharashtra, India
[8] Columbia Univ, Med Ctr, New York, NY USA
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Global Res & Dev, Paris, France
[11] UZ Leuven, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
631
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/HER2-negative (HER2-) postmenopausal women: Final analysis of the French observational TANGO study
    Villanueva, C.
    Yazbek, G.
    Beuzeboc, P.
    Viel, E.
    Dohollou, N.
    Luporsi, E.
    Eymard, J-C.
    Levy, E.
    Mouret-Reynier, M-A.
    Dourthe, L-M.
    Malaurie, E.
    Madelenat, M.
    Denden, A.
    Antoine, E-C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [4] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in Europe.
    Jerusalem, Guy Heinrich Maria
    Neven, Patrick
    Marinsek, Nina
    Zhang, Jie
    Degun, Ravi
    Benelli, Giancarlo
    Saletan, Stephen
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Ribociclib (RIB) plus fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen K. L.
    Im, Seock-Ah
    Fasching, Peter A.
    DeLaurentiis, Michelino
    Petrakova, Katarina
    Bianchi, Giulia Valeria
    Esteva, Francisco J.
    Martin, Miguel
    Pivot, Xavier
    Vidam, Gena
    Wang, Yingbo
    Lorenc, Cristina Karen Rodriguez
    Miller, Michelle Kristine
    Taran, Tanya
    Jerusalem, Guy Heinrich Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
    Janni, Wolfgang
    Burris, Howard A.
    Blackwell, Kimberly L.
    Hart, Lowell L.
    Chan, Arlene
    Nusch, Arnd
    Burdaeva, Olga Nikolaevna
    Alba, Emilio
    Yardley, Denise A.
    Bachelot, Thomas Denis
    Gil, Miguel J. Gil
    Richards, Donald A.
    Sparano, Joseph A.
    Kattan, Joseph Gergi
    Bourgeois, Hugues Pierre
    El Karak, Fadi Rafic
    Ramaswamy, Bhuvaneswari
    Sutradhar, Santosh C.
    Miller, Michelle Kristine
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)
    Yap, Y. S.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Kim, S. J.
    Aruga, T.
    Toyama, T.
    Saeki, T.
    Yamanaka, T.
    Saito, M.
    Watanabe, J.
    Takahashi, M.
    Nakamura, S.
    Inoue, K.
    Suarez-Vizcarra, J.
    He, W.
    Solovieff, N.
    Su, F.
    Chiu, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 13 - +
  • [10] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
12345